Karyopharm Therapeutics KPTI
NASDAQ KPTI
$0.80 -0.07 (-8.05%)
At close: Oct 2, 2026 · 4:00 PM EDT

Karyopharm Therapeutics (KPTI) Asset Writedowns and Impairment (2020 - 2021)

Updated

Karyopharm Therapeutics (KPTI) posted Asset Writedowns and Impairment of $200,000 for Q3 2021, up 100.0% from the prior quarter.

Analysis

Karyopharm Therapeutics (KPTI) Asset Writedowns and Impairment (2020 - 2021) Analysis & Trends

For FY2020, Karyopharm Therapeutics' Asset Writedowns and Impairment came in at $329,000.

  • Quarterly Asset Writedowns and Impairment has run from a low of $82,000 in Q1 2021 to a high of $329,000 in Q4 2020 over five years.
  • According to Business Quant data, Asset Writedowns and Impairment for the three prior quarters was $100,000 (Q2 2021), $82,000 (Q1 2021) and $329,000 (Q4 2020).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Karyopharm Therapeutics 23.15 Mn -203.27 Mn 32.35 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2021 200,000.00
Jun 30, 2021 100,000.00
Mar 31, 2021 82,000.00
Dec 31, 2020 329,000.00
API Access

Karyopharm Therapeutics Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=KPTI&period=max&api_key=YOUR_API_KEY